Tozorakimab Met Primary Endpoint in Both Oberon and Titania Phase III Trials in Patients With COPD
March 28, 2026
March 28, 2026
WILMINGTON, Delaware, March 28 -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD
First-ever IL-33-targeting biologic to demonstrate statistically significant and highly clinically meaningful reductions in COPD exacerbations in two replicate Phase III clinical trials
*
Positive high-level results fr . . .
* * *
Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD
First-ever IL-33-targeting biologic to demonstrate statistically significant and highly clinically meaningful reductions in COPD exacerbations in two replicate Phase III clinical trials
*
Positive high-level results fr . . .